Everolimus-eluting bioresorbable vascular scaffolds: final results of the ABSORB EXTEND three-year follow-up trial

Quali risultati clinici a lungo termine degli scaffold vascolari bioriassorbibili nei pazienti con complessità bassa o moderata? (Catheter Cardiovasc Interv 2018 Oct 4)

9 Ottobre Ott 2018 2 months ago
  • Bartorelli A

There is still limited data on the very long term clinical outcomes after ABSORB BRS in daily practice. A new study evaluates the 3 year-performance of the Absorb bioresorbable vascular scaffolds for the treatment of low/moderate complexity patients enrolled in the ABSORB EXTEND trial.

At three-year follow-up, the use of ABSORB in low/moderate complex PCI was associated with low and acceptable rates of major adverse clinical events, despite the infrequent use of the recommended contemporary scaffold deployment technique. However, scaffold thrombosis rate was higher than reported with current generation of metallic DES.


Reference
1. Costa JR Jr, Abizaid A, Whitbourn R, Serruys PW, Jepson N, Steinwender C, Stuteville M, Ediebah D, Sudhir K, Bartorelli AL; ABSORB EXTEND investigators. Three-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Final results of the ABSORB EXTEND trial. Catheter Cardiovasc Interv 2018 Oct 4. doi: 10.1002/ccd.27715. [Epub ahead of print] Go to PubMed